This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	AT rich interactive domain 1A (ARID1A); ARID1B; breast cancer 1 early onset (BRCA1); BRCA2; K-Ras (KRAS); phosphoinositide 3-kinase (PI3K)	Genetic studies identified mutations in chromatin-remodeling genes that could be corrected to help treat carcinosarcomas. Whole-exome sequencing of 22 gynecological carcinosarcomal tumors and matching normal tissues from patients identified previously unknown mutations in <i>ARID1A</i> , <i>ARID1B</i> and other chromatin-remodeling genes. Sequencing also identified mutations in multiple genes—including <i>BRCA1</i> , <i>BRCA2</i> , <i>KRAS</i> and <i>PI3K</i> —encoding targets associated with other cancers but not previously considered targets in carcinosarcomas. Next steps could include investigating the gene mutations and their downstream effects to identify therapeutic targets for carcinosarcomas.	Patent and licensing status unavailable	Jones, S. <i>et al. Nat. Commun.</i> ; published online Sept. 19, 2014; doi:10.1038/ncomms6006 Contact: Victor E. Velculescu, The Johns Hopkins University School of Medicine, Baltimore, Md. e-mail: velculescu@jhmi.edu Contact: Christoph Lengauer, Blueprint Medicines, Cambridge, Mass. e-mail: clengauer@blueprintmedicines.com
<i>SciBX</i> 7(41); doi:10.1038/scibx.2014.1201 Published online Oct. 23, 2014				